Keyphrases
Neuroblastoma
98%
Juvenile Dermatomyositis
87%
T Cells
73%
Organoids
51%
Galectin-9 (Gal-9)
47%
Disease Activity
44%
CXCL10
44%
MHC Class II
35%
Adoptive Cell Therapy
31%
Interferon Signature
31%
Single-cell RNA Sequencing (scRNA-seq)
30%
TIGIT
28%
Integrative Analysis
27%
Nectin-2
27%
Biomarker Profile
27%
Treatment Response
27%
High-risk Neuroblastoma
27%
Natural Killer Cells
26%
Tumor
24%
Tumor Cells
22%
Immunomodulatory
21%
TNF Receptor 2 (TNFR2)
20%
Localized Scleroderma
19%
CCL18
19%
Endothelial Cells
18%
Killing Assay
18%
Patient-derived Organoids
17%
Pediatric
17%
Serum Levels
17%
Pediatric Tumors
16%
Systemic Autoimmune Diseases
16%
Tissue Inflammation
16%
Solid Tumors
16%
Working Diagnosis
16%
Inflammation
16%
Endothelial Dysfunction
16%
Autoantibodies
15%
T-cell Mediated
14%
Tissue Residency
14%
Connective Tissue Disease
13%
Antiphospholipid Syndrome
13%
Specific Adaptation
13%
Materno-fetal Interface
13%
Siglec
13%
STAT3 mutation
13%
Three-dimensional Modeling
13%
Co-culture System
13%
Anticancer Immunotherapy
13%
Personalised Assessment
13%
Midkine
13%
Immunology and Microbiology
T Cell
88%
Dermatomyositis
82%
Immunotherapy
61%
Organoid
52%
interferon
42%
Cytotoxicity
35%
Ecalectin
33%
RNA Sequence
28%
Tumor Cell
26%
Natural Killer Cell
26%
T Cell Receptor
23%
CXCL10
22%
Blood Level
20%
Autoantibodies
19%
CCL18
19%
Localized Scleroderma
19%
Immunity
16%
Tumor Necrosis Factor Receptor 2
16%
Systemic Autoimmune Disease
15%
Cell Lineage
13%
Programmed Death-Ligand 1
13%
Sialoadhesin
13%
Midkine
13%
Migration Inhibition Factor
13%
Immunogenicity
13%
Cell Interaction
13%
Systemic Lupus Erythematosus
13%
Antiphospholipid Syndrome
13%
Regulatory T Cell
13%
5' Nucleotidase
13%
Connective Tissue
13%
Oxygen Consumption
13%
Autoimmunity
13%
STAT3
13%
Prednisone
13%
Immunosuppressive Drug
13%
CD69
12%
Major Histocompatibility Complex
11%
Eosinophilic Fasciitis
11%
Survival Rate
10%
Galectin 1
9%
CXCL13
9%
B Cell
9%
Natural Killer T Cell
9%
Myeloid
9%
Syngenic
9%
Coculture
8%
Myositis
8%
Immunology
8%
Immunoassay
7%
Medicine and Dentistry
Ganglioneuroblastoma
100%
Immunotherapy
83%
T Cell
79%
Organoid
64%
Neoplasm
32%
Cell Therapy
31%
Solid Malignant Neoplasm
30%
RNA Sequence
28%
Tumor Cell
26%
In Vitro
25%
Natural Killer Cell
23%
Immunity
20%
Cytotoxicity
18%
Childhood Cancer
15%
Pediatrics
15%
Immunogenicity
15%
T Lymphocyte Receptor
14%
Juvenile Dermatomyositis
13%
Tumor Microenvironment
13%
Cytotoxicity Assay
13%
Midkine
13%
Migration Inhibition Factor
13%
Cell Lineage
13%
Cardiorespiratory
13%
Pontine Glioma
13%
Immunosuppressive Drug
11%
Pediatric Cancer
11%
Major Histocompatibility Complex
10%
Chemotherapy
10%
Dinutuximab
9%
Histone Deacetylase Inhibitor
8%
Programmed Death-Ligand 1
7%
Immunocompetent Cell
7%
Survival Rate
7%
Secretion (Process)
7%
T Cell Receptor
6%
Ex Vivo
5%
Tumor Infiltrating Lymphocyte
5%
Neuroblastoma Cell
5%
Neuroblastoma Cell Line
5%
Pediatrics Patient
5%
Side Effect
5%
B Cell
5%
Natural Killer Cell
5%
